Page last updated: 2024-10-19

melatonin and Glaucoma

melatonin has been researched along with Glaucoma in 33 studies

Glaucoma: An ocular disease, occurring in many forms, having as its primary characteristics an unstable or a sustained increase in the intraocular pressure which the eye cannot withstand without damage to its structure or impairment of its function. The consequences of the increased pressure may be manifested in a variety of symptoms, depending upon type and severity, such as excavation of the optic disk, hardness of the eyeball, corneal anesthesia, reduced visual acuity, seeing of colored halos around lights, disturbed dark adaptation, visual field defects, and headaches. (Dictionary of Visual Science, 4th ed)

Research Excerpts

ExcerptRelevanceReference
"To study the levels of melatonin in the aqueous humour of normotensive and hypertensive intraocular pressure (IOP) patients and to compare them to an animal model of glaucoma."7.85Elevated intraocular pressure increases melatonin levels in the aqueous humour. ( Alkozi, H; Carracedo, G; de Lara, MJ; Fonseca, B; Martinez-Aguila, A; Pintor, J; Sánchez-Naves, J, 2017)
"Melatonin is a pineal hormone that has a capacity to lower intraocular pressure; it exhibits neuroprotective and antioxidant properties that make it possible to use melatonin in the therapy of glaucoma."7.85[Novel agonists of melatonin receptors as promising hypotensive and neuroprotective agents for therapy of glaucoma]. ( Beznos, OV; Chesnokova, NB; Grigoryev, AV; Lozinskaya, NA; Volkova, MS; Zaryanova, EV; Zefirov, NA, 2017)
" Using both control C57BL/6J and glaucomatous DBA/2J mice as well as TonoLab tonometry, this study evaluated the effect of melatonin and 5-methoxycarbonylamino-N-acetyltryptamine (5-MCA-NAT) when glaucomatous pathology was fully established and compared pharmacological behavior in treated mice versus control mice."7.83Effect of Melatonin and 5-Methoxycarbonylamino-N-Acetyltryptamine on the Intraocular Pressure of Normal and Glaucomatous Mice. ( Fonseca, B; Martínez-Águila, A; Pérez de Lara, MJ; Pintor, J, 2016)
"Melatonin is currently considered a promising drug for glaucoma treatment because of its ocular hypotensive and neuroprotective effects."7.79Melatonin and its analog 5-methoxycarbonylamino-N-acetyltryptamine potentiate adrenergic receptor-mediated ocular hypotensive effects in rabbits: significance for combination therapy in glaucoma. ( Crooke, A; Huete-Toral, F; Martín-Gil, A; Martínez-Águila, A; Pintor, J, 2013)
"We explored the melatonin influence on the level of amino acid neurotransmitters of the retina in glaucoma neuropathy in rats."7.79[Protective action of melatonin in experimental glaucoma in rats]. ( Mykheĭtseva, IM, 2013)
"Melatonin, the MT(2) melatonin receptor agonist IIK7 [N-butanoyl-2-(2-methoxy-6H-isoindolo[2,1-a]indol-11-yl)ethanamine], and the putative MT(3) melatonin receptor agonist 5-MCA-NAT [5-methoxycarbonylamino-N-acetyltryptamine] have previously been shown to reduce intraocular pressure (IOP) in ocular normotensive rabbits."7.77Design of novel melatonin analogs for the reduction of intraocular pressure in normotensive rabbits. ( Alarma-Estrany, P; Guzman-Aranguez, A; Huete, F; Pelaez, T; Peral, A; Pintor, J; Plourde, R; Yerxa, B, 2011)
"As previous studies have suggested that melatonin and serotonin may be involved in the regulation of intraocular pressure, retinal concentrations of melatonin, 5-HT, and related indoleamines measured at day and at night were studied during the development of a glaucoma-like disorder with increased intraocular pressure in the al mutant quail."7.70Day and night dysfunction in intraretinal melatonin and related indoleamines metabolism, correlated with the development of glaucoma-like disorder in an avian model. ( Chanut, E; Dkhissi, O; Nguyen-Legros, J; Repérant, J; Trouvin, JH; Versaux-Botteri, C, 1998)
"The possible involvement of a melatonergic mechanism in the control of intraocular pressure (IOP) and the genesis of light-induced avian glaucoma (LIAG) was studied by measuring N-acetyltransferase (NAT) activity and melatonin levels in the iris, ciliary body and retina-choroid during the course of LIAG development, and in normal subjects by day and night."7.67N-acetyltransferase activity and melatonin level in the eyes of glaucomatous chickens. ( Aimoto, T; Chiou, GC; Lauber, JK; Rohde, BH, 1985)
"Melatonin is a hormone secreted into the blood mainly from the pineal gland allowing the entrainment of the circadian rhythms of several biological functions."6.48Update in glaucoma medicinal chemistry: emerging evidence for the importance of melatonin analogues. ( Colligris, B; Crooke, A; Pintor, J, 2012)
"Glaucoma is a frequent ophthalmologic condition leading to chronic progressive optic neuropathy, which can result in visual impairment and blindness."6.47The role of melatonin in glaucoma: implications concerning pathophysiological relevance and therapeutic potential. ( Agorastos, A; Huber, CG, 2011)
"Acute ocular hypertension (AOH) is the most important characteristic of acute glaucoma, which can lead to retinal ganglion cell (RGC) death and permanent vision loss."5.72Anti-PANoptosis is involved in neuroprotective effects of melatonin in acute ocular hypertension model. ( Bai, X; Cui, K; Fan, M; Feng, Y; Hu, C; Huang, J; Huang, W; Liang, X; Liao, J; Lu, P; Shi, Y; Tang, X; Xu, F; Xu, Y; Ye, D, 2022)
"Glaucoma is a blindness-causing disease that involves selective damage to retinal ganglion cells (RGCs) and their axons."5.62Melatonin Prevents Non-image-Forming Visual System Alterations Induced by Experimental Glaucoma in Rats. ( Aranda, ML; Calanni, JS; Devouassoux, J; Dieguez, HH; Dorfman, D; González Fleitas, MF; Iaquinandi, A; Rosenstein, RE; Sande, PH, 2021)
"Concomitantly, gliosis-related inflammation and the Bax-associated apoptosis were partially prevented, thus leading to RGC survival and recovered retinal dysfunction."5.56A Topical Formulation of Melatoninergic Compounds Exerts Strong Hypotensive and Neuroprotective Effects in a Rat Model of Hypertensive Glaucoma. ( Amato, R; Bagnoli, P; Cammalleri, M; Corsaro, R; Dal Monte, M; Pezzino, S; Rusciano, D, 2020)
"Glaucoma is a leading cause of blindness."5.36Melatonin: a novel neuroprotectant for the treatment of glaucoma. ( Belforte, NA; Chianelli, MS; de Zavalía, N; Keller Sarmiento, MI; Moreno, MC; Rosenstein, RE; Sande, PH, 2010)
"We aimed to compare the neuroprotective effects of brimonidine tartrate (BRT) and melatonin (MEL) on retinal ganglion cells (RGCs) in a rat glaucoma model."3.88Comparison of the neuroprotective effects of brimonidine tartrate and melatonin on retinal ganglion cells. ( Ciftci, F; Eyuboglu, S; Gumusel, A; Guzel, E; Marangoz, D; Seckin, I; Yalvac, I; Yilmaz, B, 2018)
"To study the levels of melatonin in the aqueous humour of normotensive and hypertensive intraocular pressure (IOP) patients and to compare them to an animal model of glaucoma."3.85Elevated intraocular pressure increases melatonin levels in the aqueous humour. ( Alkozi, H; Carracedo, G; de Lara, MJ; Fonseca, B; Martinez-Aguila, A; Pintor, J; Sánchez-Naves, J, 2017)
"Melatonin is a pineal hormone that has a capacity to lower intraocular pressure; it exhibits neuroprotective and antioxidant properties that make it possible to use melatonin in the therapy of glaucoma."3.85[Novel agonists of melatonin receptors as promising hypotensive and neuroprotective agents for therapy of glaucoma]. ( Beznos, OV; Chesnokova, NB; Grigoryev, AV; Lozinskaya, NA; Volkova, MS; Zaryanova, EV; Zefirov, NA, 2017)
" Using both control C57BL/6J and glaucomatous DBA/2J mice as well as TonoLab tonometry, this study evaluated the effect of melatonin and 5-methoxycarbonylamino-N-acetyltryptamine (5-MCA-NAT) when glaucomatous pathology was fully established and compared pharmacological behavior in treated mice versus control mice."3.83Effect of Melatonin and 5-Methoxycarbonylamino-N-Acetyltryptamine on the Intraocular Pressure of Normal and Glaucomatous Mice. ( Fonseca, B; Martínez-Águila, A; Pérez de Lara, MJ; Pintor, J, 2016)
"Melatonin is currently considered a promising drug for glaucoma treatment because of its ocular hypotensive and neuroprotective effects."3.79Melatonin and its analog 5-methoxycarbonylamino-N-acetyltryptamine potentiate adrenergic receptor-mediated ocular hypotensive effects in rabbits: significance for combination therapy in glaucoma. ( Crooke, A; Huete-Toral, F; Martín-Gil, A; Martínez-Águila, A; Pintor, J, 2013)
"We explored the melatonin influence on the level of amino acid neurotransmitters of the retina in glaucoma neuropathy in rats."3.79[Protective action of melatonin in experimental glaucoma in rats]. ( Mykheĭtseva, IM, 2013)
"Melatonin, the MT(2) melatonin receptor agonist IIK7 [N-butanoyl-2-(2-methoxy-6H-isoindolo[2,1-a]indol-11-yl)ethanamine], and the putative MT(3) melatonin receptor agonist 5-MCA-NAT [5-methoxycarbonylamino-N-acetyltryptamine] have previously been shown to reduce intraocular pressure (IOP) in ocular normotensive rabbits."3.77Design of novel melatonin analogs for the reduction of intraocular pressure in normotensive rabbits. ( Alarma-Estrany, P; Guzman-Aranguez, A; Huete, F; Pelaez, T; Peral, A; Pintor, J; Plourde, R; Yerxa, B, 2011)
"As previous studies have suggested that melatonin and serotonin may be involved in the regulation of intraocular pressure, retinal concentrations of melatonin, 5-HT, and related indoleamines measured at day and at night were studied during the development of a glaucoma-like disorder with increased intraocular pressure in the al mutant quail."3.70Day and night dysfunction in intraretinal melatonin and related indoleamines metabolism, correlated with the development of glaucoma-like disorder in an avian model. ( Chanut, E; Dkhissi, O; Nguyen-Legros, J; Repérant, J; Trouvin, JH; Versaux-Botteri, C, 1998)
" Here we describe three experiments which investigated: (i) the effects of sleep in five groups of subjects: glaucoma, suspect glaucoma, young high-normal IOP, old high-normal IOP groups and an elderly control group, (ii) the effect of exposure to bright light (2500 lux) during sleep on associated IOP changes, and (iii) the relationship between changes in IOP and plasma melatonin during sleep."3.68Investigation of parameters influencing intraocular pressure increases during sleep. ( Brown, B; Eyeson-Annan, M; Fletcher, T; Swann, PG; Wildsoet, C, 1993)
"Melatonin is a hormone secreted into the blood mainly from the pineal gland allowing the entrainment of the circadian rhythms of several biological functions."2.48Update in glaucoma medicinal chemistry: emerging evidence for the importance of melatonin analogues. ( Colligris, B; Crooke, A; Pintor, J, 2012)
"Glaucoma is a neurodegenerative pathology that affects the optic nerve producing blindness."2.45New treatments for ocular hypertension. ( Alarma-Estrany, P; Mediero, A; Pintor, J, 2009)
"Acute ocular hypertension (AOH) is the most important characteristic of acute glaucoma, which can lead to retinal ganglion cell (RGC) death and permanent vision loss."1.72Anti-PANoptosis is involved in neuroprotective effects of melatonin in acute ocular hypertension model. ( Bai, X; Cui, K; Fan, M; Feng, Y; Hu, C; Huang, J; Huang, W; Liang, X; Liao, J; Lu, P; Shi, Y; Tang, X; Xu, F; Xu, Y; Ye, D, 2022)
"Melatonin (MT) is an indole neuroendocrine hormone mainly secreted by the pineal gland."1.72The neuroprotective effect of melatonin in glutamate excitotoxicity of R28 cells and mouse retinal ganglion cells. ( An, Y; Ding, L; Li, H; Song, S; Wang, C; Xia, X; Xia, Z; Zhou, X, 2022)
"Concomitantly, gliosis-related inflammation and the Bax-associated apoptosis were partially prevented, thus leading to RGC survival and recovered retinal dysfunction."1.56A Topical Formulation of Melatoninergic Compounds Exerts Strong Hypotensive and Neuroprotective Effects in a Rat Model of Hypertensive Glaucoma. ( Amato, R; Bagnoli, P; Cammalleri, M; Corsaro, R; Dal Monte, M; Pezzino, S; Rusciano, D, 2020)
"Glaucoma is a multifactorial neurodegenerative disorder and one of the leading causes of irreversible blindness globally and for which intraocular pressure is the only modifiable risk factor."1.51Simultaneous co-delivery of neuroprotective drugs from multi-loaded PLGA microspheres for the treatment of glaucoma. ( Arranz-Romera, A; Bravo-Osuna, I; Cordeiro, MF; Davis, BM; Esteban-Pérez, S; Guo, L; Herrero-Vanrell, R; Molina-Martínez, IT; Ravindran, N; Shamsher, E, 2019)
"Glaucoma is a leading cause of blindness worldwide, characterized by retinal ganglion cell degeneration and damage to the optic nerve."1.37Effect of experimental glaucoma on the non-image forming visual system. ( Belforte, N; de Zavalía, N; Fernandez, DC; Golombek, DA; Lanzani, MF; Plano, SA; Rosenstein, RE; Salido, E; Sarmiento, MI, 2011)
"Glaucoma is a leading cause of blindness."1.36Melatonin: a novel neuroprotectant for the treatment of glaucoma. ( Belforte, NA; Chianelli, MS; de Zavalía, N; Keller Sarmiento, MI; Moreno, MC; Rosenstein, RE; Sande, PH, 2010)
"Glaucoma is an optic neuropathy in which retinal ganglion cells die probably through an apoptotic process."1.32Retinal oxidative stress induced by high intraocular pressure. ( Campanelli, J; Keller Sarmiento, MI; Moreno, MC; Rosenstein, RE; Sande, P; Sánez, DA, 2004)

Research

Studies (33)

TimeframeStudies, this research(%)All Research%
pre-19903 (9.09)18.7374
1990's2 (6.06)18.2507
2000's5 (15.15)29.6817
2010's15 (45.45)24.3611
2020's8 (24.24)2.80

Authors

AuthorsStudies
Ye, D1
Xu, Y1
Shi, Y1
Fan, M1
Lu, P1
Bai, X1
Feng, Y1
Hu, C1
Cui, K1
Tang, X1
Liao, J1
Huang, W1
Xu, F1
Liang, X1
Huang, J1
Wang, C1
An, Y1
Xia, Z1
Zhou, X1
Li, H1
Song, S1
Ding, L1
Xia, X1
Alkozi, HA1
Navarro, G1
Franco, R1
Pintor, J7
Scuderi, L1
Davinelli, S1
Iodice, CM1
Bartollino, S1
Scapagnini, G1
Costagliola, C1
Scuderi, G1
Yoshikawa, T1
Obayashi, K1
Miyata, K1
Saeki, K1
Ogata, N1
Adornetto, A1
Rombolà, L1
Morrone, LA1
Nucci, C1
Corasaniti, MT1
Bagetta, G1
Russo, R1
Dal Monte, M1
Cammalleri, M1
Amato, R1
Pezzino, S1
Corsaro, R1
Bagnoli, P1
Rusciano, D1
Martínez-Águila, A4
Martín-Gil, A2
Carpena-Torres, C1
Pastrana, C1
Carracedo, G2
González Fleitas, MF1
Devouassoux, J1
Aranda, ML1
Dieguez, HH1
Calanni, JS1
Iaquinandi, A1
Sande, PH2
Dorfman, D1
Rosenstein, RE7
Marangoz, D1
Guzel, E1
Eyuboglu, S1
Gumusel, A1
Seckin, I1
Ciftci, F1
Yilmaz, B1
Yalvac, I1
Arranz-Romera, A1
Davis, BM1
Bravo-Osuna, I1
Esteban-Pérez, S1
Molina-Martínez, IT1
Shamsher, E1
Ravindran, N1
Guo, L1
Cordeiro, MF1
Herrero-Vanrell, R1
Crooke, A2
Huete-Toral, F1
Mykheĭtseva, IM1
Münch, M1
Léon, L1
Collomb, S1
Kawasaki, A1
Fonseca, B2
Pérez de Lara, MJ1
Alkozi, H1
Sánchez-Naves, J1
de Lara, MJ1
Chesnokova, NB1
Beznos, OV1
Lozinskaya, NA1
Volkova, MS1
Zaryanova, EV1
Zefirov, NA1
Grigoryev, AV1
Mediero, A1
Alarma-Estrany, P2
Belforte, NA1
Moreno, MC3
de Zavalía, N3
Chianelli, MS1
Keller Sarmiento, MI3
Pandi-Perumal, SR2
Srinivasan, V2
Spence, DW1
Brown, GM1
Cardinali, DP2
Agorastos, A1
Huber, CG1
Guzman-Aranguez, A1
Huete, F1
Peral, A1
Plourde, R1
Pelaez, T1
Yerxa, B1
Plano, SA1
Fernandez, DC1
Lanzani, MF1
Salido, E1
Belforte, N1
Sarmiento, MI1
Golombek, DA1
Colligris, B1
Campanelli, J1
Sande, P2
Sánez, DA1
Marcos, HA1
Siu, AW1
Maldonado, M1
Sanchez-Hidalgo, M1
Tan, DX1
Reiter, RJ1
Lundmark, PO1
Rudin, DO1
Wildsoet, C1
Eyeson-Annan, M1
Brown, B1
Swann, PG1
Fletcher, T1
Dkhissi, O1
Chanut, E1
Versaux-Botteri, C1
Trouvin, JH1
Repérant, J1
Nguyen-Legros, J1
Lauber, JK2
Oishi, T1
Vriend, J1
Aimoto, T1
Rohde, BH1
Chiou, GC1

Reviews

10 reviews available for melatonin and Glaucoma

ArticleYear
Melatonin and the control of intraocular pressure.
    Progress in retinal and eye research, 2020, Volume: 75

    Topics: Animals; Aqueous Humor; Glaucoma; Humans; Intraocular Pressure; Melatonin

2020
Melatonin: Implications for Ocular Disease and Therapeutic Potential.
    Current pharmaceutical design, 2019, Volume: 25, Issue:39

    Topics: Aging; Eye; Free Radicals; Glaucoma; Humans; Melatonin; Uveitis

2019
Natural Products: Evidence for Neuroprotection to Be Exploited in Glaucoma.
    Nutrients, 2020, Oct-16, Volume: 12, Issue:10

    Topics: Amides; Biological Products; Colforsin; Curcumin; Cytidine Diphosphate Choline; Dietary Supplements;

2020
Influence of Circadian Rhythm in the Eye: Significance of Melatonin in Glaucoma.
    Biomolecules, 2021, 02-24, Volume: 11, Issue:3

    Topics: Animals; Circadian Rhythm; Dry Eye Syndromes; Glaucoma; Humans; Intraocular Pressure; Melatonin; Myo

2021
New treatments for ocular hypertension.
    Autonomic neuroscience : basic & clinical, 2009, May-11, Volume: 147, Issue:1-2

    Topics: Adrenergic Agents; Animals; Eye; Glaucoma; Humans; Melatonin; Neuropharmacology; Nucleotides; Ocular

2009
Melatonin as a therapeutic tool in ophthalmology: implications for glaucoma and uveitis.
    Journal of pineal research, 2010, Volume: 49, Issue:1

    Topics: Animals; Glaucoma; Humans; Melatonin; Neuroprotective Agents; Ophthalmology; Receptors, Melatonin; U

2010
The role of melatonin in glaucoma: implications concerning pathophysiological relevance and therapeutic potential.
    Journal of pineal research, 2011, Volume: 50, Issue:1

    Topics: Animals; Circadian Rhythm; Glaucoma; Humans; Melatonin; Retinal Ganglion Cells

2011
Update in glaucoma medicinal chemistry: emerging evidence for the importance of melatonin analogues.
    Current medicinal chemistry, 2012, Volume: 19, Issue:21

    Topics: Animals; Chemistry, Pharmaceutical; Glaucoma; Humans; Intraocular Pressure; Melatonin; Molecular Str

2012
Protective effects of melatonin in experimental free radical-related ocular diseases.
    Journal of pineal research, 2006, Volume: 40, Issue:2

    Topics: Antioxidants; Cataract; Eye Diseases; Glaucoma; Humans; Keratitis; Melatonin; Ocular Physiological P

2006
Melatonin in the eye: implications for glaucoma.
    Experimental eye research, 2007, Volume: 84, Issue:6

    Topics: Animals; Antioxidants; Eye; Glaucoma; Humans; Intraocular Pressure; Melatonin; Oxidative Stress; Rec

2007

Trials

1 trial available for melatonin and Glaucoma

ArticleYear
Decreased melatonin secretion in patients with glaucoma: Quantitative association with glaucoma severity in the LIGHT study.
    Journal of pineal research, 2020, Volume: 69, Issue:2

    Topics: Aged; Aged, 80 and over; Circadian Rhythm; Female; Glaucoma; Humans; Male; Melatonin; Middle Aged; S

2020

Other Studies

22 other studies available for melatonin and Glaucoma

ArticleYear
Anti-PANoptosis is involved in neuroprotective effects of melatonin in acute ocular hypertension model.
    Journal of pineal research, 2022, Volume: 73, Issue:4

    Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Caspase 8; DNA Nucleotidylexotransferase;

2022
The neuroprotective effect of melatonin in glutamate excitotoxicity of R28 cells and mouse retinal ganglion cells.
    Frontiers in endocrinology, 2022, Volume: 13

    Topics: Animals; Glaucoma; Glutamic Acid; Melatonin; Mice; N-Methylaspartate; Neuroprotective Agents; Reacti

2022
A Topical Formulation of Melatoninergic Compounds Exerts Strong Hypotensive and Neuroprotective Effects in a Rat Model of Hypertensive Glaucoma.
    International journal of molecular sciences, 2020, Dec-04, Volume: 21, Issue:23

    Topics: Acetamides; Animals; Antihypertensive Agents; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Dise

2020
Melatonin Prevents Non-image-Forming Visual System Alterations Induced by Experimental Glaucoma in Rats.
    Molecular neurobiology, 2021, Volume: 58, Issue:8

    Topics: Animals; Antioxidants; Glaucoma; Light; Male; Melatonin; Rats; Rats, Wistar; Retinal Ganglion Cells;

2021
Comparison of the neuroprotective effects of brimonidine tartrate and melatonin on retinal ganglion cells.
    International ophthalmology, 2018, Volume: 38, Issue:6

    Topics: Animals; Antioxidants; Apoptosis; Brimonidine Tartrate; Disease Models, Animal; Glaucoma; Intraocula

2018
Simultaneous co-delivery of neuroprotective drugs from multi-loaded PLGA microspheres for the treatment of glaucoma.
    Journal of controlled release : official journal of the Controlled Release Society, 2019, 03-10, Volume: 297

    Topics: Animals; Dexamethasone; Disease Models, Animal; Drug Carriers; Drug Compounding; Drug Liberation; Dr

2019
Melatonin and its analog 5-methoxycarbonylamino-N-acetyltryptamine potentiate adrenergic receptor-mediated ocular hypotensive effects in rabbits: significance for combination therapy in glaucoma.
    The Journal of pharmacology and experimental therapeutics, 2013, Volume: 346, Issue:1

    Topics: Adrenergic Agonists; Adrenergic alpha-2 Receptor Agonists; Adrenergic beta-Antagonists; Animals; Cel

2013
[Protective action of melatonin in experimental glaucoma in rats].
    Fiziolohichnyi zhurnal (Kiev, Ukraine : 1994), 2013, Volume: 59, Issue:1

    Topics: Animals; Antioxidants; Aspartic Acid; Chromatography, Ion Exchange; Epinephrine; gamma-Aminobutyric

2013
Comparison of acute non-visual bright light responses in patients with optic nerve disease, glaucoma and healthy controls.
    Scientific reports, 2015, Oct-19, Volume: 5

    Topics: Adult; Case-Control Studies; Female; Glaucoma; Humans; Light; Male; Melatonin; Middle Aged; Optic Ne

2015
Effect of Melatonin and 5-Methoxycarbonylamino-N-Acetyltryptamine on the Intraocular Pressure of Normal and Glaucomatous Mice.
    The Journal of pharmacology and experimental therapeutics, 2016, Volume: 357, Issue:2

    Topics: Animals; Dose-Response Relationship, Drug; Glaucoma; Intraocular Pressure; Melatonin; Mice; Mice, In

2016
Elevated intraocular pressure increases melatonin levels in the aqueous humour.
    Acta ophthalmologica, 2017, Volume: 95, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Animals; Aqueous Humor; Biomarkers; Chromatography, High Pressure Li

2017
[Novel agonists of melatonin receptors as promising hypotensive and neuroprotective agents for therapy of glaucoma].
    Biomeditsinskaia khimiia, 2017, Volume: 63, Issue:1

    Topics: Animals; Antioxidants; Drug Design; Gene Expression; Glaucoma; Indoles; Intraocular Pressure; Ligand

2017
Melatonin: a novel neuroprotectant for the treatment of glaucoma.
    Journal of pineal research, 2010, Volume: 48, Issue:4

    Topics: Animals; Arginine; gamma-Aminobutyric Acid; Glaucoma; Glutamate Decarboxylase; Glutamic Acid; Histoc

2010
Design of novel melatonin analogs for the reduction of intraocular pressure in normotensive rabbits.
    The Journal of pharmacology and experimental therapeutics, 2011, Volume: 337, Issue:3

    Topics: Animals; Dose-Response Relationship, Drug; Drug Design; Eye; Glaucoma; Intraocular Pressure; Isoindo

2011
Effect of experimental glaucoma on the non-image forming visual system.
    Journal of neurochemistry, 2011, Volume: 117, Issue:5

    Topics: Animals; Anterior Eye Segment; Blotting, Western; Cell Count; Chondroitin Sulfates; Eye; Glaucoma; I

2011
Retinal oxidative stress induced by high intraocular pressure.
    Free radical biology & medicine, 2004, Sep-15, Volume: 37, Issue:6

    Topics: Animals; Antioxidants; Free Radicals; Glaucoma; Glutathione; Hyaluronic Acid; Intraocular Pressure;

2004
Effect of glaucoma on the retinal glutamate/glutamine cycle activity.
    FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2005, Volume: 19, Issue:9

    Topics: Animals; Glaucoma; Glutamate-Ammonia Ligase; Glutamic Acid; Glutaminase; Glutamine; Hyaluronic Acid;

2005
Glaucoma, "auditory glaucoma", "articular glaucoma" and the third eye.
    Medical hypotheses, 1980, Volume: 6, Issue:4

    Topics: Arthritis; Basement Membrane; Cell Membrane Permeability; Glaucoma; Humans; Lipid Metabolism; Melato

1980
Investigation of parameters influencing intraocular pressure increases during sleep.
    Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists), 1993, Volume: 13, Issue:4

    Topics: Adult; Age Factors; Aged; Female; Glaucoma; Humans; Intraocular Pressure; Light; Male; Melatonin; Mi

1993
Day and night dysfunction in intraretinal melatonin and related indoleamines metabolism, correlated with the development of glaucoma-like disorder in an avian model.
    Journal of neuroendocrinology, 1998, Volume: 10, Issue:11

    Topics: Acetylserotonin O-Methyltransferase; Aging; Amines; Animals; Circadian Rhythm; Coturnix; Glaucoma; H

1998
Plasma melatonin rhythm lost in preglaucomatous chicks.
    Journal of ocular pharmacology, 1986,Summer, Volume: 2, Issue:3

    Topics: Animals; Chickens; Circadian Rhythm; Corticosterone; Glaucoma; Light; Melatonin; Thyroxine

1986
N-acetyltransferase activity and melatonin level in the eyes of glaucomatous chickens.
    Journal of ocular pharmacology, 1985,Summer, Volume: 1, Issue:2

    Topics: Acetyltransferases; Animals; Arylamine N-Acetyltransferase; Chickens; Choline O-Acetyltransferase; E

1985